Neurology Central

Cannabidiol for epilepsy expected to be available within 6 weeks: industry news round-up

This week’s industry news round-up reveals the latest updates including a new medicine for migraine, a rescheduling of cannabidiol for epilepsy and a successful Phase III trial for neuromyelitis optica spectrum disorder. Find out more about our selection of the highlights below.
Our selection of the highlights includes:

Emgality™ receives marketing authorization for the prevention of migraine

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for Emgality™ (galcanezumab), a monoclonal antibody for the prevention of migraine.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.